AJP - Regu Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol 293: R2218-R2224, 2007. First published September 26, 2007; doi:10.1152/ajpregu.00295.2007
0363-6119/07 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Information
Right arrow All Versions of this Article:
293/6/R2218    most recent
00295.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mundy, A. L.
Right arrow Articles by Barton, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mundy, A. L.
Right arrow Articles by Barton, M.

INFLAMMATION AND CYTOKINES

Endothelin stimulates vascular hydroxyl radical formation: effect of obesity

Alexa L. Mundy,* Elvira Haas,* Indranil Bhattacharya,* Corinne C. Widmer, Martin Kretz, Karin Baumann, and Matthias Barton

Molecular Internal Medicine, Medical Policlinic, Department of Internal Medicine, University Hospital Zurich, Zürich, Switzerland

Submitted 27 April 2007 ; accepted in final form 19 September 2007


   ABSTRACT
TOP
 ABSTRACT
METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Reactive oxygen species (ROS) and endothelin-1 (ET-1) contribute to vascular pathophysiology in obesity. In this context, whether ET-1 modulates hydroxyl radical (bulletOH) formation and the function of ROS/bulletOH in obesity is not known. In the present study, formation and function of ROS, including bulletOH, were investigated in the aorta of lean and leptin-deficient obese ob/ob mice. Hydroxyl radical formation was detected ex vivo using terephthalic acid in intact aortic rings and the involvement of ROS in ET-1-mediated vasoreactivity was analyzed using the antioxidant EPC-K1, a combination of {alpha}-tocopherol and ascorbic acid. Generation of either bulletOH, bulletO2–, and H2O2 was strongly inhibited by EPC-K1 (all P < 0.05). In obese mice, basal vascular bulletOH formation and ROS activity were reduced by 3-fold and 5-fold, respectively (P < 0.05 vs. lean). ET-1 markedly enhanced bulletOH formation in lean (6-fold, P < 0.05 vs. untreated) but not in obese mice. Obesity increased ET-1-induced contractions (P < 0.05 vs. lean), and ROS scavenging further enhanced the response (P < 0.05 vs. untreated). Exogenous ROS, including bulletOH caused stronger vasodilation in obese animals (P < 0.05 vs. lean), whereas endothelium-dependent relaxation was similar between lean and obese animals. In conclusion, we present a sensitive method allowing ex vivo measurement of vascular bulletOH generation and provide evidence that ET-1 regulates vascular bulletOH formation. The data indicate that in obesity, vascular formation of ROS, including bulletOH is lower, whereas the sensitivity to ROS is increased, suggesting a novel and important role of ROS, including bulletOH in the regulation of vascular tone in disease status associated with increased body weight.

oxidative stress; acetylcholine; vasoconstriction; murine; ob/ob; terephthalic acid; vitamin E; vitamin C

ENDOTHELIN-1 ( ET-1) IS A POTENT vasoconstrictor (57) and mitogen (30) that has also been implicated in the pathogenesis of metabolic diseases, including obesity and diabetes (4, 29, 31, 43). Endogenous ET-1 contributes to increased basal vascular tone in human obesity (8, 31), and we and others have shown that vascular responsiveness to ET-1 is enhanced in obesity (8, 50). Recent evidence also suggests that ET-1 stimulates the generation of certain reactive oxygen species (ROS) (26, 52).

ROS are short-lived, oxygen intermediates that participate in activation of intracellular signaling pathways (48) and regulate cell function (14), and they are known to contribute to abnormal vascular reactivity in obesity-related diseases such as diabetes, atherosclerosis, and hypertension (16, 41, 44, 46, 48, 55). Although vascular effects of ROS have been often regarded as deleterious, resulting in impaired vasodilation and/or enhanced vasoconstriction (45), ROS also have beneficial effects; indeed, superoxide (bulletO2–), hydrogen peroxide (H2O2), and the hydroxyl radical (bulletOH) may also act as vasodilators under certain conditions (40, 53).

Previous studies have investigated vascular interactions between ET-1 and bulletO2– or H2O2 (26, 52); however, little is known about whether ET-1 also interacts with bulletOH, a highly reactive ROS (33). Hydroxyl radical is mainly formed by H2O2 via either the Fenton (13) or the Haber-Weiss reaction (23):

Formula

Formula

At high concentrations, hydroxyl radicals can cause membrane damage, DNA and RNA fragmentation, and lipid peroxidation (9, 49). In the vasculature, bulletOH regulates vasoconstriction (49) and vasodilation (40) under normal and pathological conditions (39, 40).

The aim of the present study was to characterize the interactions between ET-1 and ROS/bulletOH in the vasculature of normal C57BL6/J laboratory mice and to determine the possible modulatory effects of obesity on ROS-mediated vascular tone and bulletOH production using a model of leptin-deficient obesity.


   METHODS
TOP
 ABSTRACT
 METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Animals

Healthy 40-wk-old male C57BL/6 mice (controls) and severely obese leptin-deficient mice (B6.V-Lepob/J; Charles River, Sulzfeld Germany; obese) were used. Body weight of obese mice was 58 ± 4 g compared with 29 ± 1 g for control mice. Animals were held at the institutional animal facilities and received standard rodent chow and tap water ad libitum. Housing facilities and experimental protocols were approved by the local authorities for animal research (Kommission für Tierversuche des Kantons Zürich, Switzerland) and conform to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 1996). Mice were anesthetized (xylazine: 100 mg/kg body wt; ketamine: 23 mg/kg body wt; and acepromazine: 3.0 mg/kg body wt ip), and exsanguinated via cardiac puncture.

Measurement of Vascular Hydroxyl Radical Formation

To quantify bulletOH generation in very small specimens of living vascular tissue ex vivo, we established a method using terephthalic acid (TPA), a specific probe for bulletOH detection, slightly modified from published in vitro protocols (3, 42). Hydroxylation of TPA yields a stable and highly specific isomer (2-hydroxyl terephthalic acid, TPA-OH) (42) that is not formed by reaction with either superoxide or hydroperoxides (3). The sensitivity and specificity of TPA to detect bulletOH are comparable to that of the spin trap 5,5 dimethyl-1-pyrroline N-oxide (27), as detected by electron spin resonance technique (see also supplemental information, which may be found online at the American Journal of Physiology—Regulatory, Integrative and Comparative Physiology website). Vascular bulletOH generation was measured in aortic rings, which were left unconstricted and placed in gassed Krebs solution (95% O2, 5% CO2, 37°C, pH 7.4) for 4 h containing 2.5 mM TPA in the absence (basal bulletOH formation) or in the presence of 10–6 mol/l ET-1 (ET-1-stimulated bulletOH formation). TPA-OH was quantified fluorometrically (excitation: 326 nm, emission: 432 nm) using a microplate reader (SpectraMax M2) (42). Hydroxyl radical formation was calculated as relative light units per milligram of protein after subtraction of background fluorescence. Protein was extracted from vascular tissue in a RIPA buffer containing orthovanadate, PMSF, and complete mini protease inhibitor (Roche, Rotkreuz, Switzerland) using a cell shredder (Qiagen, Hombrechtikon, Switzerland) and incubated for 30 min at 4°C. Insoluble material was separated by centrifugation and protein content of the soluble fraction was quantified using Bio-Rad Protein Assay solution (Bio-Rad, Reinach, Switzerland), according to the manufacturer's instructions.

Characterization of the Antioxidant Activities of EPC-K1

The effects of EPC-K1 on bulletO2– and bulletOH formation and on the stability of H2O2 were determined using specific assays (12). The radical scavenger EPC-K1, a water-soluble compound, is a combination of two known antioxidants, vitamin E (alpha-tocopherol) and vitamin C (ascorbic acid) (54) linked by a phosphate diester (See also supplemental information that is available online at the American Journal Physiology—Regulatory, Integrative and Comparative Physiology website.). Effects of EPC-K1 (10–1 mg/ml) on xanthine/xanthine oxidase-mediated bulletO2– generation were determined by L-012-dependent chemiluminescence, as described (10). The overall measuring time was 6 min, and a total of 24 measurements were taken during this period. Each measurement was for 10 s, and the interval between each reading was 5 s (Lumat LB 9507, Berthold Technologies, Regensdorf, Switzerland). Total superoxide anion formation was determined by cumulative measurements of chemiluminescence over 6 min and calculated after subtracting the background. Hydroxyl radical was generated from the reaction of Fe2+ and ascorbic acid (51) (both at 100 µmol/l) in warm, gassed Krebs solution (37°C, 95% O2, 5% CO2), in the presence or absence of EPC-K1 (10–1 mg/ml) (35), and quantified using TPA (2.5 mM) hydroxylation (42). The effect of EPC-K1 (10–1 mg/ml) on hydrogen peroxide (0.3 µmol/l H2O2) was assessed using the Amplex Red assay (Molecular Probes, Eugene, OR), as previously described (18). The reaction product resorufin (18) was detected fluorometrically (excitation and emission wavelengths: 571 nm and 585 nm, respectively) using a SpectraMax M2 (see also supplemental information online at the American Journal of Physiology—Regulatory, Integrative and Comparative Physiology website).

Vascular Function Studies

The aorta was excised and placed in cold (4°C) Krebs-Ringer bicarbonate solution [in mmol/l: NaCl 118.6; KCl 4.7; CaCl2 2.5; MgSO4 1.2; KH2PO4 1.2; NaHCO3 25.1; ethylenediaminetetraacetic acid calcium disodium salt (EDTANa2Ca) 0.026; glucose 10.1], dissected free of connective tissue under a microscope (Olympus SZX9, Volketswil, Switzerland), and cut into rings 3 mm in length. Special care was taken not to damage the endothelium during this procedure. Segments of thoracic aorta were mounted onto tungsten wires (100 µm in diameter) and transferred to water-jacketed organ baths containing Krebs solution (95% O2,-5% CO2 at 37°C, pH 7.4) and connected to force transducers (Hugo Sachs Elektronik, March-Hugstetten, Germany) (50). Resting tension was gradually increased to the optimal level as previously described (50); vessels were repeatedly exposed to 100 mM KCl until a stable contraction response was achieved.

Endothelium-dependent and -independent vascular function. Endothelium-dependent relaxation to ACh (0.1–10 µmol/l) was determined in the presence of indomethacin (10 µmol/l, a nonselective cyclooxygenase inhibitor, 30 min preincubation) in rings preconstricted with phenylephrine to 80% of KCl-induced contraction, as previously described (5). Endothelium-independent vasodilation was investigated using the nitric oxide (NO) donor sodium nitroprusside (10 µmol/l).

Reactive oxygen species and basal vascular tone. Rings were pretreated with L-nitro-arginine methyl ester (L-NAME, 300 µmol/l) for 15 min to block effects of endogenous NO (24). To determine whether endogenous ROS formation contributes to basal vascular tone, the ROS scavenger EPC-K1 (10–1 mg/ml equal to 141.46 µM) (35) was applied to quiescent vascular rings and the resultant contraction, reflecting basal vascular ROS generation (6, 20) was measured. The contractile responses of quiescent vessels to scavengers or enzyme inhibitors allow us to indirectly quantify basal generation of molecules such as NO or bulletO2– in a particular vascular bed (6, 20).

Vascular responses to ET-1. Vascular rings were exposed to ET-1 (0.01–300 nmol/l) in the presence of L-NAME (300 µmol/l) for 30 min, as described (56). To investigate the role of ROS for ET-1-induced contraction, selected rings were also preincubated with the ROS scavenger EPC-K1 (10–1 mg/ml) for 15 min.

Effects of ROS on vascular tone. Vascular responses to exogenously generated ROS/bulletOH generated by the reaction between Fe2+ and ascorbic acid (51) were investigated in aortic rings preconstricted with phenylephrine, as previously described (36).

Gene Expression Measurements

Steady-state mRNA expression levels of vascular nitric oxide synthase (NOS) isoforms 2 and 3 were determined by real-time quantitative reverse transcriptase-PCR. Aortic total RNA was extracted using the RNeasy micro kit for RNA isolation from fibrous tissues (Qiagen, Hilden, Germany). Purity of RNA was controlled by RT(–) reactions (PCR with nontranscribed RNA). RNA was reverse-transcribed with the Omniscript RT kit (Qiagen, Hilden, Germany). Real-time quantitative PCR was used to determine relative expression levels of murine genes encoding for NOS2 (Nos2, locus: NM_010927 [GenBank] ), NOS3 (Nos3, locus: NM_008713 [GenBank] ) and the housekeeping gene tyrosine-3-monooxygenase (locus: NM_011740 [GenBank] ). For amplification of a tyrosine-3-monooxygenase-specific cDNA fragment 5'-CGA GCA GGC AGA GCG ATA TG-3' was used as the forward and 5'-AGA CGA CCC TCC ACG ATG AC-3' as the reverse primer, for a Nos2-specific fragment 5'-GCA CCG AGA TTG GAG TTC-3' as the forward and 5'-AGC ACA GCC ACA TTG ATC-3' as the reverse primer. 5'-CCT AGT CCT CGC CTC CTTC-3' was used as the forward primer for a Nos3-specific fragment and 5'-ACC ACT TCC ATT CTT CGT AGC-3' as the reverse primer. Two-step PCR was performed with iQ SYBR Supermix PCR kit (Bio-Rad) as follows: activation of the hot start Taq polymerase for 3 min (95°C), followed by 40 cycles of denaturation at 95°C for 15 s (step 1), and annealing and extension at 60°C for 1 min (step 2). Fluorescence was detected at the end of each extension step. Identity and specificity of amplicons were confirmed by agarose gel electrophoresis, melting curve analysis, and sequencing (Microsynth, Balgach, Switzerland). Steady-state mRNA expression levels were calculated by normalizing the relative amount of each mRNA to the housekeeping gene tyrosine-3-monooxygenase (28) and expressed as arbitrary units (AU).

Materials

ET-1 and L-NAME were from Alexis Corp (Lausanne, Switzerland). EPC-K1 was from Senju Pharmaceuticals (Osaka, Japan). L-012 was from Wako Chemicals (Neuss, Germany), and Amplex Red was from Molecular Probes (Eugene, OR). All other chemicals were from Sigma Chemicals (Buchs, Switzerland).

Statistical Analyses

Data are given as means ± SE, and n denotes the number of animals used per experiment. Contraction is expressed as a percentage of 100 mM KCl-induced contraction, and dilations are given as a percentage of the maximal contraction. EC50 values (as negative logarithm pD2) were calculated by nonlinear regression analysis, and area under the curve was calculated for each individual curve using SigmaPlot (SPSS Chicago, IL). Data were analyzed using ANOVA for repeated measurements with Bonferroni correction, the Mann-Whitney U-test, or unpaired Student's t-test when appropriate. A P value <0.05 was considered significant.


   RESULTS
TOP
 ABSTRACT
 METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Efficacy of bulletOH-Generating Systems in Krebs Solution

Hydroxyl radical generation was determined in vitro by TPA, a specific probe for bulletOH (27). The efficacy of bulletOH generated by ascorbic acid and Fe2+ was compared with another bulletOH-generating system consisting of H2O2 and Fe2+. The amount of bulletOH generated by vitamin C and Fe2+ was 2.6-fold higher compared with H2O2 and Fe2+ (P < 0.05 vs. H2O2 and Fe2+, Table 1). DMSO, a known bulletOH scavenger (1), blocked in either system bulletOH formation by ~80%, as shown in Table 1 (See also supplemental data for this article, which is available online at the American Journal of Physiology—Regulatory, Integrative and Comparative Physiology website.).


View this table:
[in this window]
[in a new window]

  		Table 1. Efficacy of in vitro bulletOH-generating systems

 
Vascular Hydroxyl Radical Formation and Acute Effects of ET-1

TPA was used to quantify vascular bulletOH formation ex vivo. Formation of bulletOH was detected under basal conditions in uncontracted aortic rings from control mice [2.5 ± 0.1 relative fluorescence units (RFU)/mg protein, Fig. 1A] and markedly increased by endothelin-1 (15.0 ± 1.0 RFU/mg protein, sixfold, P < 0.0001, vs. untreated, Fig. 1B). Basal bulletOH formation was reduced approximately threefold in obese animals (P < 0.0001 vs. lean, Fig. 1, A and B) and ET-1 slightly increased this attenuated bulletOH formation (0.6 ± 0.1 to 2.3 ± 0.3 RFU/mg protein, P < 0.0001 vs. untreated, Fig. 1B). Interestingly, ET-1-stimulated bulletOH formation in obese mice was still below basal levels of bulletOH detected in lean mice (2.3 ± 0.3 vs. 2.5 ± 0.1 RFU/mg protein, respectively).


Figure 1
View larger version (6K):
[in this window]
[in a new window]

  		Fig. 1. Vascular bulletOH formation in lean control (open bars) and obese ob/ob mice (solid bars), as measured by TPA hydroxylation. Under unstimulated conditions basal formation of bulletOH was detected. Obesity reduced basal bulletOH formation by three-fold (P < 0.001 vs. lean). Exposure to endothelin-1 (ET-1) (10–6 mol/l) increased bulletOH formation in lean control mice but had only a small effect in obese mice. Values are expressed as fluorescence units per milligram protein; n = 6/group *P < 0.001 vs. basal; {dagger}P < 0.001 vs. lean.

 
Effects of EPC-K1 on ROS Formation and Vascular Tone

The effects of EPC-K1 on in vitro generation of bulletO2–, bulletOH, and H2O2 were determined. EPC-K1 inhibited xanthine-oxidase-mediated bulletO2– generation by 74 ± 2% (P < 0.0001 vs. control), that of ascorbic acid and Fe2+-mediated bulletOH formation by 84 ± 1% (P < 0.0001 vs. control), and that of H2O2 by 61 ± 2% (P < 0.0001 vs. control). We next investigated basal ROS bioactivity in quiescent aortic rings by measuring changes in vascular tone after applying EPC-K1, which caused contraction in all rings investigated (P < 0.05, vs. untreated, Fig. 2). EPC-K1-induced contractions were markedly reduced in obese mice (5-fold, P < 0.05, vs. control).


Figure 2
View larger version (7K):
[in this window]
[in a new window]

  		Fig. 2. Basal reactive oxygen species (ROS) formation in quiescent aortic rings expressed as a change in basal vascular tone in response to the ROS scavenger EPC-K1. Inhibition of basal ROS resulted in contraction in all vessels studied. In obesity, basal ROS formation was markedly reduced (fivefold, P < 0.05). Contractions to EPC-K1 are expressed as a percentage of KCl-induced contractions. n = 5–14/group. *P < 0.05 vs. lean.

 
Effects of Exogenous ROS on Vascular Tone

The addition of exogenous ROS/bulletOH to precontracted vascular rings caused a vasodilator response (P < 0.0001, vs. untreated, Fig. 3, ROS/bulletOH in Fig. 3A), that was enhanced threefold by obesity (P < 0.05 vs. control).


Figure 3
View larger version (7K):
[in this window]
[in a new window]

  		Fig. 3. Dilator responses to exogenous ROS/bulletOH (A) and endothelium-dependent relaxation to ACh (B) in aortic rings of lean and obese animals precontracted with phenylephrine. Dilations to ROS/bulletOH are expressed as a percentage of precontraction. n = 5–14/group. *P < 0.05 vs. lean. Relaxation to ACh is expressed as percent of precontraction. n = 7–9/group.

 
Function and Expression of Vascular NO Synthases

NO-mediated endothelium-dependent relaxation to ACh was similar in lean and obese mice [–94 ± 1.6 vs. –94 ± 3.3%, not significant (ns), Fig. 3B], as was relaxation to sodium nitroprusside (SNP) (–109 ± 1.3 vs. –107 ± 1.5%). Similarly, vascular expression of NOS3 mRNA was similar between control (504 ± 53 AU) and obese mice (471 ± 74 AU, ns), as were NOS2 mRNA levels (control, 1.2 ± 1 AU, n = 4; obese, 0.95 ± 0.35 AU, n = 7, ns).

Effect of Endogenous ROS on ET-1-Induced Contractility

Contractions to ET-1 were enhanced by obesity (20.4 ± 4.9% vs. 10.6 ± 1.5%, P < 0.05, Fig. 4, A and B and Table 2). In obese mice, scavenging of ROS by EPC-K1 further enhanced ET-1-induced vasoconstriction (45 ± 9%, P < 0.05 vs. untreated); this effect was absent in lean controls (Fig. 4).


Figure 4
View larger version (12K):
[in this window]
[in a new window]

  		Fig. 4. Contractions to ET-1 (0.01–300 nmol/l) in the presence of L-NAME in aorta of lean (open symbols) and obese mice (solid symbols) in untreated rings (left), and after preincubation with EPC-K1 (right). Obesity was associated with increased contractions to ET-1, and ROS scavenging increased contractions to ET-1 in obese animals only. Data are expressed as a percentage of contraction to 100 mM KCl; n = 8–19 /group. *P < 0.05 vs. lean. {dagger}P < 0.05 vs. untreated.

 

View this table:
[in this window]
[in a new window]

  		Table 2. pD2 values and values of area under the ET-1 concentration-response curve (AUC)

 

   DISCUSSION
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
This study demonstrates interactions between the vasoconstrictor ET-1 and ROS/bulletOH under normal conditions and in obesity. We present a sensitive method to quantify hydroxyl radical formation in small vascular specimens ex vivo, using TPA hydroxylation, and show that ET-1 acutely stimulates vascular bulletOH formation in the aorta of normal laboratory mice. The results provide evidence that basal ROS activity, as well as ET-1-stimulated bulletOH formation were markedly reduced in obesity. Scavenging of endogenous ROS with the nonselective radical scavenger EPC-K1 increased vasoconstrictor responses to ET-1 in aortic rings of obese animals, but not in controls, indicating that ROS antagonize ET-1-mediated vasoconstrictor responses in obesity.

bulletOH is a highly reactive ROS, and its role in pathophysiology has only been clarified in part (17, 25, 48). Investigations on the role of bulletOH in the pathophysiology of cardiovascular disorders have, to date, been hindered by the lack of sensitive and specific methods. Previously, salicylic acid has been used to detect bulletOH formation (11). However, because salicylic acid also detects peroxynitrite (19) and inhibits enzymes involved in ROS production (7, 21), salicylic acid cannot be considered a specific probe for bulletOH. Therefore, one of the goals of the present study was to establish a specific and sensitive method that would allow us to measure bulletOH generation in small vascular specimens ex vivo. We used TPA, which is a highly specific and sensitive probe for bulletOH (3), as shown by electron spin resonance experiments (27) (see also supplemental information online at the American Journal of Physiology—Regulatory, Integrative and Comparative Physiology website), and therefore, no other probes for bulletOH were used in our experiments. Using the TPA-based bulletOH detection method, the present study shows that basal bulletOH formation can indeed be detected in very small specimens of arterial tissue in both lean and obese animals.

Endothelin contributes to the pathogenesis of atherosclerosis, hypertension, and diabetes (30, 43) and has been previously shown to stimulate the generation of ROS such as bulletO2– and H2O2 (26, 52). Presently, there is no information on whether ET-1 modulates vascular formation of bulletOH. Using TPA as a probe for bulletOH, we found that ET-1 is a potent stimulus of vascular bulletOH formation in animals with normal body weight. An unexpected finding of the present study was that this stimulating effect of ET-1 was more or less abrogated in obese mice. Because of the limitations in tissue and animals, only a single concentration of bulletOH was used. To our knowledge, this is not only the first demonstration that ET-1 modulates vascular bulletOH formation, but also that both basal and stimulated bulletOH formation are markedly reduced in obesity. In line with these results, basal vascular activity of ROS, as measured indirectly by EPC-K1-induced contractions, was also reduced in obese animals. Our study did not identify the nature of ROS mediating the observed effects in response to EPC-K1. One of the potential candidates of ROS could be bulletO2– as in a most recent study using young obese db/db mice, which express a mutated leptin receptor and unlike the ob/ob animals used in our study show high circulating leptin levels, Griendling and colleagues (41) demonstrated that aortic membrane superoxide generation was enhanced compared with lean controls.

EPC-K1 has been previously proposed to be a scavenger that is selective for bulletOH (35). On the basis of its chemical structure that combines ascorbic acid and {alpha}-tocopherol linked by a phosphodiester, it is very unlikely to be specific for bulletOH scavenging (54). Indeed, our results now show that EPC-K1 not only scavenges bulletOH but also that it potently inactivates bulletO2– and H2O2. Therefore, in the experiments involving EPC-K1, scavenging of any of the ROS mentioned may contribute to the observed changes in vasoreactivity. According to a previous report, EPC-K1 as a ROS scavenger induces NO-independent relaxation in precontracted canine coronary arteries (47). In the present study, however, we demonstrate that EPC-K1 also causes contraction of quiescent murine aortic rings, reflecting basal ROS vasodilator bioactivity. These differences in the effects of EPC-K1 are likely to be explained by 1) the state of contraction of the vascular rings, 2) by the type of artery studied and/or 3) by interspecies differences.

To investigate the effects of exogenous ROS/bulletOH on vascular tone, we used ascorbic acid and iron (45, 49) as a ROS/bulletOH generating system. In vitro experiments confirmed that this system is indeed a strong inductor of bulletOH formation and that concentration-dependent relaxation can be achieved (see supplemental information for details). The results of the present study demonstrate that exogenous ROS/bulletOH cause vasodilation, an effect that is markedly enhanced by obesity. This suggests that obesity modulates the sensitivity of the vasculature to vasodilator activities of ROS. Also, it is likely that obesity per se and not leptin deficiency enhances the responsiveness to ROS/bulletOH, since enhanced vascular relaxation to ROS/bulletOH was also observed in a model of diet-induced obesity (36). An unexpected finding was that no differences in the NO-mediated endothelium-dependent relaxation in the presence of cyclooxygenase inhibitors were seen between obese and lean animals. The steady-state mRNA expression levels of endothelial nitric oxide synthase (eNOS/NOS3) was also similar between the groups. Of note, in these experiments, a cyclooxygenase inhibitor was used since obesity enhances cyclooxygenase-mediated production of vasoconstrictor prostanoids (36, 50), which attenuate endothelium-dependent vascular relaxation in response to ACh in obesity (50). In a recent study, endothelium-dependent relaxation was found to be impaired in the aorta of obese db/db mice (41), which is likely to be explained by the lack of a cyclooxygenase inhibitor in the organ chamber experiments (50). The results of the present study are in line with previous studies showing that in the presence of cyclooxygenase inhibition, NO-dependent relaxation actually remains unaffected in diet-induced, as well as in monogenetic forms of obesity in rodents (2, 22, 36).

Similar to our recent study using a model of diet-induced obesity (50), we found that contractions to ET-1 are also increased in obesity due to leptin deficiency. The role of ROS for ET-1-induced contractions was investigated using the ROS scavenger EPC-K1. While in lean animals, EPC-K1 had no effect on contractions to ET-1, the antioxidant markedly enhanced contractions in obese animals, suggesting that endogenous ROS antagonize ET-1-mediated vasoconstriction in obesity, but not under normal conditions. The present data also suggest that this indirect vasodilator activity of ROS in obesity is independent of NO, since all experiments were performed in the presence of a NO synthase inhibitor. Indeed, reactive oxygen species have been shown to block vasoconstriction and mediate vasorelaxant effects in the vasculature by 1) activation of endothelium-dependent hyperpolarizing factor (32, 37), 2) by activating cGMP pathway (15, 34), and/or 3) by inhibition of phosphorylation of myosin light chain protein (38). In the present study, because NOS was blocked, cyclic GMP is unlikely to play a role in the ROS-mediated responses observed. We would like to again emphasize that the findings of ET-1-induced bulletOH generation and the observed changes in vasoreactivity are two independent observations (tissue specimens vs. arterial rings on passive tension), which were made under different conditions. Therefore, ET-1-derived bulletOH generation is unlikely to be the sole mechanistic link for the observed changes in vasoreactivity.

Perspective

The present study demonstrates novel vascular effects and interactions between ET-1 and ROS/bulletOH under normal conditions and in states of obesity, in particular. Furthermore, the data presented here suggest possible "protective" vasodilator activities of ROS/bulletOH, which are altered in obesity. The possible pathophysiologicial significance of these observations in human obesity and/or insulin resistance remains yet to be shown. However, the activation of direct and indirect ROS-mediated vasodilator mechanisms may explain the clinical observation that only some, but not all, obese patients develop hypertension.


   GRANTS
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This work was supported by the Swiss National Science Foundation (SCORE 3200-058426.99, 3232-058421.99, and 3200-108258/1), and the Hanne Liebermann Stiftung, Zürich.


   ACKNOWLEDGMENTS
 
The authors gratefully acknowledge the expert technical assistance of Emerita Ammann and thank Senju, Osaka, Japan for providing EPC-K1.


   FOOTNOTES
 

Address for reprint requests and other correspondence: M. Barton, Medical Policlinic, Dept. of Internal Medicine, Univ. Hospital Zurich, Raemistrasse 100, 8091 Zurich, Switzerland (e-mail: barton{at}usz.ch)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

* These authors contributed equally to this article. Back


   REFERENCES
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Alam MS, Ku K, Yamauchi M, Hashimoto M, Nosaka S, Hossain MS, Masumura S, Nakayama K, Tamura K. Protective effects of nicaraven, a new hydroxyl radical scavenger, on the endothelial dysfunction after exposure of pig coronary artery to hydroxyl radicals. Mol Cell Biochem 178: 237–243, 1998.[CrossRef][Web of Science][Medline]
  2. Andrews TJ, Laight DW, Anggard EE, Carrier MJ. Investigation of endothelial hyperreactivity in the obese Zucker rat in-situ: reversal by vitamin E. J Pharm Pharmacol 52: 83–86, 2000.[CrossRef][Web of Science][Medline]
  3. Barreto JC, Smith GS, Strobel NH, McQuillin PA, Miller TA. Terephthalic acid: a dosimeter for the detection of hydroxyl radicals in vitro [Online]. Life Sci 56: PL89–96, 1995.[CrossRef][Web of Science][Medline]
  4. Barton M, d'Uscio LV, Shaw S, Meyer P, Moreau P, Luscher TF. ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 31: 499–504, 1998.[Abstract/Free Full Text]
  5. Barton M, Haudenschild CC, d'Uscio LV, Shaw S, Munter K, Luscher TF. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 95: 14367–14372, 1998.[Abstract/Free Full Text]
  6. Barton M, Vos I, Shaw S, Boer P, D'Uscio LV, Grone HJ, Rabelink TJ, Lattmann T, Moreau P, Luscher TF. Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis. J Am Soc Nephrol 11: 835–845, 2000.[Abstract/Free Full Text]
  7. Bomalaski JS, Hirata F, Clark MA. Aspirin inhibits phospholipase C. Biochem Biophys Res Commun 139: 115–121, 1986.[CrossRef][Web of Science][Medline]
  8. Cardillo C, Campia U, Iantorno M, Panza JA. Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension 43: 36–40, 2004.[Abstract/Free Full Text]
  9. Chen SX, Schopfer P. Hydroxyl-radical production in physiological reactions. A novel function of peroxidase. Eur J Biochem 260: 726–735, 1999.[Web of Science][Medline]
  10. Daiber A, August M, Baldus S, Wendt M, Oelze M, Sydow K, Kleschyov AL, Munzel T. Measurement of NAD(P)H oxidase-derived superoxide with the luminol analogue L-012. Free Radic Biol Med 36: 101–111, 2004.[CrossRef][Web of Science][Medline]
  11. Delbarre B, Floyd RA, Delbarre G, Calinon F. Glutamate accumulation and increased hydroxyl free radical formation in the abdominal aorta and heart of gerbil after ischemia/reperfusion insult. Free Radic Biol Med 13: 31–34, 1992.[CrossRef][Web of Science][Medline]
  12. Dikalov S, Griendling KK, Harrison DG. Measurement of reactive oxygen species in cardiovascular studies. Hypertension 49: 717–727, 2007.[Free Full Text]
  13. Dikalova AE, Kadiiska MB, Mason RP. An in vivo ESR spin-trapping study: free radical generation in rats from formate intoxication—role of the Fenton reaction. Proc Natl Acad Sci USA 98: 13549–13553, 2001.[Abstract/Free Full Text]
  14. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 82: 47–95, 2002.[Abstract/Free Full Text]
  15. Fujimoto S, Asano T, Sakai M, Sakurai K, Takagi D, Yoshimoto N, Itoh T. Mechanisms of hydrogen peroxide-induced relaxation in rabbit mesenteric small artery. Eur J Pharmacol 412: 291–300, 2001.[CrossRef][Web of Science][Medline]
  16. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114: 1752–1761, 2004.[CrossRef][Web of Science][Medline]
  17. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 108: 1912–1916, 2003.[Free Full Text]
  18. Gutheil WG, Stefanova ME, Nicholas RA. Fluorescent coupled enzyme assays for D-alanine: application to penicillin-binding protein and vancomycin activity assays. Anal Biochem 287: 196–202, 2000.[CrossRef][Web of Science][Medline]
  19. Halliwell B, Kaur H. Hydroxylation of salicylate and phenylalanine as assays for hydroxyl radicals: a cautionary note visited for the third time. Free Radic Res 27: 239–244, 1997.[Web of Science][Medline]
  20. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci USA 89: 11259–11263, 1992.[Abstract/Free Full Text]
  21. Hinz B, Kraus V, Pahl A, Brune K. Salicylate metabolites inhibit cyclooxygenase-2-dependent prostaglandin E(2) synthesis in murine macrophages. Biochem Biophys Res Commun 274: 197–202, 2000.[CrossRef][Web of Science][Medline]
  22. Howarth AG, Wiehler WB, Pannirselvam M, Jiang Y, Berger JP, Severson D, Anderson TJ, Triggle CR. A nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist reverses endothelial dysfunction in diabetic (db/db-/-) mice. J Pharmacol Exp Ther 316: 364–370, 2006.[Abstract/Free Full Text]
  23. Ingelman-Sundberg M, Johansson I. Mechanisms of hydroxyl radical formation and ethanol oxidation by ethanol-inducible and other forms of rabbit liver microsomal cytochromes P-450. J Biol Chem 259: 6447–6458, 1984.[Abstract/Free Full Text]
  24. Kretz M, Mundy AL, Widmer CC, Barton M. Early aging and anatomic heterogeneity determine cyclooxygenase-mediated vasoconstriction to angiotensin II in mice. J Cardiovasc Pharmacol 48: 30–33, 2006.[CrossRef][Web of Science][Medline]
  25. Li J, Li W, Liu W, Altura BT, Altura BM. Mechanisms of hydroxyl radical-induced contraction of rat aorta. Eur J Pharmacol 499: 171–178, 2004.[CrossRef][Web of Science][Medline]
  26. Li L, Fink GD, Watts SW, Northcott CA, Galligan JJ, Pagano PJ, Chen AF. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation 107: 1053–1058, 2003.[Abstract/Free Full Text]
  27. Linxiang L, Abe Y, Nagasawa Y, Kudo R, Usui N, Imai K, Mashino T, Mochizuki M, Miyata N. An HPLC assay of hydroxyl radicals by the hydroxylation reaction of terephthalic acid. Biomed Chromatogr 18: 470–474, 2004.[CrossRef][Web of Science][Medline]
  28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402–408, 2001.[CrossRef][Web of Science][Medline]
  29. Lteif A, Vaishnava P, Baron AD, Mather KJ. Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes 56: 728–734, 2007.[Abstract/Free Full Text]
  30. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102: 2434–2440, 2000.[Abstract/Free Full Text]
  31. Mather KJ, Mirzamohammadi B, Lteif A, Steinberg HO, Baron AD. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes 51: 3517–3523, 2002.[Abstract/Free Full Text]
  32. Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, Kanaide H, Takeshita A. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest 106: 1521–1530, 2000.[Web of Science][Medline]
  33. Michaels HB, Hunt JW. Reactions of the hydroxyl radical with polynucleotides. Radiat Res 56: 57–70, 1973.[CrossRef][Web of Science][Medline]
  34. Mittal CK, Murad F. Activation of guanylate cyclase by superoxide dismutase and hydroxyl radical: a physiological regulator of guanosine 3',5'-monophosphate formation. Proc Natl Acad Sci USA 74: 4360–4364, 1977.[Abstract/Free Full Text]
  35. Mori A, Edamatsu R, Kohno M, Ohmori S. A new hydroxyl radical scavenger: EPC-K1. Neurosciences 15: 371–376, 1989.[CrossRef]
  36. Mundy AL, Haas E, Bhattacharya I, Widmer CC, Kretz M, Hofmann-Lehmann R, Minotti R, Barton M. Fat intake modifies vascular responsiveness and receptor expression of vasoconstrictors: implications for diet-induced obesity. Cardiovasc Res 73: 368–375, 2007.[Abstract/Free Full Text]
  37. Ohashi M, Faraci F, Heistad D. Peroxynitrite hyperpolarizes smooth muscle and relaxes internal carotid artery in rabbit via ATP-sensitive K+ channels. Am J Physiol Heart Circ Physiol 289: H2244–H2250, 2005.[Abstract/Free Full Text]
  38. Palen DI, Ouhtit A, Belmadani S, Lucchesi PA, Matrougui K. Hydrogen peroxide acts as relaxing factor in human vascular smooth muscle cells independent of MAP-kinase and nitric oxide. Front Biosci 11: 2526–2534, 2006.[CrossRef][Web of Science][Medline]
  39. Pieper GM, Langenstroer P, Siebeneich W. Diabetic-induced endothelial dysfunction in rat aorta: role of hydroxyl radicals. Cardiovasc Res 34: 145–156, 1997.[Abstract/Free Full Text]
  40. Rubanyi GM. Vascular effects of oxygen-derived free radicals. Free Radic Biol Med 4: 107–120, 1988.[CrossRef][Web of Science][Medline]
  41. San Martin A, Du P, Dikalova A, Lassegue B, Aleman M, Gongora MC, Brown K, Joseph G, Harrison DG, Taylor WR, Jo H, Griendling KK. Reactive oxygen species-selective regulation of aortic inflammatory gene expression in Type 2 diabetes. Am J Physiol Heart Circ Physiol 292: H2073–H2082, 2007.[Abstract/Free Full Text]
  42. Saran M, Summer KH. Assaying for hydroxyl radicals: hydroxylated terephthalate is a superior fluorescence marker than hydroxylated benzoate. Free Radic Res 31: 429–436, 1999.[CrossRef][Web of Science][Medline]
  43. Schiffrin EL. Vascular endothelin in hypertension. Vascul Pharmacol 43: 19–29, 2005.[CrossRef][Web of Science][Medline]
  44. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest 116: 1813–1822, 2006.[CrossRef][Web of Science][Medline]
  45. Shen JZ, Zheng XF, Kwan CY. Differential contractile actions of reactive oxygen species on rat aorta: selective activation of ATP receptor by H2O2 [Online]. Life Sci 66: PL291–296, 2000.[CrossRef][Web of Science][Medline]
  46. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, Griendling KK. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105: 1429–1435, 2002.[Abstract/Free Full Text]
  47. Takayama H, Hamner CE, Caccitolo JA, Hisamochi K, Pearson PJ, Schaff HV. A novel antioxidant, EPC-K1, stimulates endothelial nitric oxide production and scavenges hydroxyl radicals. Circ J 67: 1046–1052, 2003.[CrossRef][Web of Science][Medline]
  48. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 42: 1075–1081, 2003.[Abstract/Free Full Text]
  49. Tosaka M, Hashiba Y, Saito N, Imai H, Shimizu T, Sasaki T. Contractile responses to reactive oxygen species in the canine basilar artery in vitro: selective inhibitory effect of MCI-186, a new hydroxyl radical scavenger. Acta Neurochir (Wien) 144: 1305–1310, 2002.[CrossRef][Medline]
  50. Traupe T, Lang M, Goettsch W, Munter K, Morawietz H, Vetter W, Barton M. Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens 20: 2239–2245, 2002.[CrossRef][Web of Science][Medline]
  51. Udenfriend S, Clark CT, Axelrod J, Brodie BB. Ascorbic acid in aromatic hydroxylation. I. A model system for aromatic hydroxylation. J Biol Chem 208: 731–739, 1954.[Free Full Text]
  52. Wedgwood S, Black SM. Endothelin-1 decreases endothelial NOS expression and activity through ETA receptor-mediated generation of hydrogen peroxide. Am J Physiol Lung Cell Mol Physiol 288: L480–L487, 2005.[Abstract/Free Full Text]
  53. Wei EP, Kontos HA, Beckman JS. Mechanisms of cerebral vasodilation by superoxide, hydrogen peroxide, and peroxynitrite. Am J Physiol Heart Circ Physiol 271: H1262–H1266, 1996.[Abstract/Free Full Text]
  54. Wei T, Chen C, Li F, Zhao B, Hou J, Xin W, Mori A. Antioxidant properties of EPC-K1: a study on mechanisms. Biophys Chem 77: 153–160, 1999.[CrossRef][Web of Science][Medline]
  55. Wellen KE, Hotamisligil GS. Inflammation, stress, diabetes. J Clin Invest 115: 1111–1119, 2005.[CrossRef][Web of Science][Medline]
  56. Widmer CC, Mundy AL, Kretz M, Barton M. Marked heterogeneity of endothelin-mediated contractility and contraction dynamics in mouse renal and femoral arteries. Exp Biol Med (Maywood) 231: 777–781, 2006.[Abstract/Free Full Text]
  57. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411–415, 1988.[CrossRef][Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Information
Right arrow All Versions of this Article:
293/6/R2218    most recent
00295.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mundy, A. L.
Right arrow Articles by Barton, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mundy, A. L.
Right arrow Articles by Barton, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.